DOCSLIB.ORG

Univerzita Komenského Fakulta Matematiky, Fyziky a Informatiky

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Univerzita Komenského Fakulta Matematiky, Fyziky a Informatiky UNIVERZITA KOMENSKÉHO FAKULTA MATEMATIKY, FYZIKY A INFORMATIKY Zoznam publikačnej činnosti Doc. RNDr. Ľubica Lacinová, DrSc. AAB Vedecké monografie vydané v domácich vydavateľstvách AAB01 Timko, Jozef - Siekel, Peter [UKOEXRP] (38% [1,85 AH]) - Turňa, Ján [UKOPRBMB] - Ferenčík, Igor - Glasa, Miroslav - Kuchta, Tomáš - Kúdela, Otakar - Lacinová, Ľubica [UKOEXFM] (17%) - Valková, Danka [UKOPRCOR] (10% [0,5 AH]): Geneticky modifikovanéorganizmy = Genetically modified organisms. - Bratislava : Veda, 2004. - 104 s. ISBN 80-224-0834-4 Ohlasy (1): [o1] 2008 Stano, J. - Micieta, K. - Korenova, M. - Blanarikova, V. - Tintemann, H. - Nemec, P. - Valsikova, M.: Study of immobilized and extracellular invertase of lemon balm. In: Chemistry of Natural Compounds, Vol. 44, No. 6, 2008, s.755-761 - SCI ; SCOPUS ABB Štúdie charakteru vedeckej monografie v časopisoch a zborníkoch vydané v domácich vydavateľstvách ABB01 Lacinová, Ľubica [UKOEXFM] (100%) : Voltage-Dependent Calcium Channels Lit. 278 zázn. In: General Physiology and Biophysics. - Vol. 24, Suppl. 1 (2005), s. 1-82 Registrované v: wos, scopus Indikátor časopisu: IF (JCR) 2005=0,560 Ohlasy (105): [o1] 2006 Chu, Z. - Moenter, S.: Physiologic regulation of a tetrodotoxin-sensitive sodium influx that mediates a slow afterdepolarization potential in gonadotropin-releasing hormone neurons: Possible implications for the central regulation offertility. In: Journal of Neuroscience, Vol. 26, No. 46, 2006, s. 11961-11973 - SCI ; SCOPUS [o1] 2006 Gill, S. - Gill, R. - Xie, Y. - Wicks, D. - Liang, D.: Development and validation of HTS flux assay for endogenously expressed chloride channels in a CHO-K1 cell line. In: Assay and Drug Development Technologies, Vol. 4, No. 1, 2006,s. 65-71 - SCI ; SCOPUS [o1] 2006 Krieger, A. - Radhakrishnan, K. - Pereverzev, A. - Siapich, S. - Banat, M. - Kamp, M. - Leroy, J. - Klockner, U. - Hescheler, J. - Weiergraber, M. - Schneider, T.: The molecular chaperone hsp70 interacts with the cytosolic II-IIIloop of the Ca v2.3 E-type voltage-gated Ca 2+ channel. In: Cellular Physiology and Biochemistry, Vol. 17, No. 3-4, 2006, s. 97-110 - SCI ; SCOPUS [o1] 2006 Mckeown, L. - Robinson, P. - Jones, O.: Molecular basis of inherited calcium channelopathies: Role of mutations in pore-forming subunits. In: Acta Pharmacologica Sinica, Vol. 27, No. 7, 2006, s. 799-812 - SCI ; SCOPUS [o1] 2006 Selim, A. - Mahon, M. - Juppner, H. - Bringhurst, F. - Divieti, P.: Role of calcium channels in carboxyl-terminal parathyroid hormone receptor signaling. In: American Journal of Physiology - Cell Physiology, Vol. 291, No. 1, 2006,Atrt. No. C114-C121 - SCOPUS [o1] 2006 Weiergraber, M. - Kamp, M. - Radhakrishnan, K. - Hescheler, J. - Schneider, T.: The Cav2.3 voltage-gated calcium channel in epileptogenesis-Shedding new light on an enigmatic channel. In: Neuroscience and Biobehavioral Reviews, Vol.30, No. 8, 2006, s. 1122-1144 - SCI ; SCOPUS [o1] 2006 Wolfe, D. - Pearce, D.: Channeling studies in yeast: Yeast as a model for channelopathies?. In: NeuroMolecular Medicine, Vol. 8, No. 3, 2006, s. 279-306 - SCI ; SCOPUS [o1] 2007 Andrade, A. - Sandoval, A. - Oviedo, N. - Waard, M. - Elias, D. - Felix, R.: Protolytic cleavage of the voltage-gated Ca2+ channel alpha(2)delta subunit: structural and functional features. In: European Journal of Neuroscience, Vol.25, No. 6, 2007, s. 1705-1710 - SCI ; SCOPUS 1 [o1] 2007 Chakraborti, S. - Das, S. - Kar, P. - Ghosh, B. - Samanta, K. - Kolley, S. - Ghosh, S. - Roy, S. - Chakraborti, T.: Calcium signaling phenomena in heart diseases: A perspective. In: Molecular and Cellular Biochemistry, Vol. 298, No.1-2, 2007, s. 1-40 - SCOPUS [o1] 2006 Felix, R.: Calcium channelopathies. In: NeuroMolecular Medicine, Vol. 8, No. 3, 2006, s. 307-318 - SCI ; SCOPUS [o1] 2007 Hull, J. - Kajigaya, R. - Imai, K. - Matsumoto, S.: Sex pheromone production in the silkworm, Bombyx mori, is mediated by store-operated Ca2+ channels. In: Bioscience, Biotechnology and Biochemistry, Vol. 71, No. 8, 2007, s.1993-2001 - SCI ; SCOPUS [o1] 2007 Katz, I. - Kim, J. - Gale, K. - Kondratyev, A.: Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain. In: Journal of Pharmacology and ExperimentalTherapeutics, Vol. 322, No. 2, 2007, s. 494-500 - SCI ; SCOPUS [o1] 2007 Lory, P. - Chemin, J.: Towards the discovery of novel T-type calcium channel blockers. In: Expert Opinion on Therapeutic Targets, Vol. 11, No. 5, 2007, s. 717-722 - SCI ; SCOPUS [o1] 2007 Ozer, M.: A comparative analysis of linear, nonlinear and improved nonlinear thermodynamic models of voltage-dependent ion channel kinetics. In: Physica A: Statistical Mechanics and Its Applications, Vol. 379, No. 2, 2007, s. 579-586- SCI ; SCOPUS [o1] 2007 Pica-Mattoccia, L. - Valle, C. - Basso, A. - Troiani, A. - Vigorosi, F. - Liberti, P. - Festucci, A. - Cioli, D.: Cytochalasin D abolishes the schistosomicidal activity of praziquantel. In: Experimental Parasitology, Vol. 115, No. 4,2007, s. 344-351 - SCI ; SCOPUS [o1] 2007 Youn, H. - Jeoung, M. - Koo, Y. - Ji, H. - Markesbery, W. - Ji, I. - Ji, T.: Kalirin is under-expressed in Alzheimer's disease hippocampus. In: Journal of Alzheimer's Disease, Vol. 11, No. 3, 2007, s. 385-397 - SCI ; SCOPUS [o1] 2007 Zhou, L. - Zhao, S. - Nadim, F.: Neuromodulation of short-term synaptic dynamics examined in a mechanistic model based on kinetics of calcium currents. In: Neurocomputing, Vol. 70, No. 10-12, 2007, s. 2050-2054 - SCI ; SCOPUS [o1] 2008 Chen, L. - Liu, C. - Liu, L.: Changes in osmolality modulate voltage-gated calcium channels in trigeminal ganglion neurons. In: Brain Research, Vol. 1208, 2008, s. 56-66 - SCI ; SCOPUS [o1] 2008 Kong, H. - Fan, Y. - Xie, J. - Ding, J. - Sha, L. - Shi, X. - Sun, X. - Hu, G.: AQP4 knockout impairs proliferation, migration and neuronal differentiation of adult neural stem cells. In: Journal of Cell Science, Vol. 121, No. 24,2008, s. 4029-4036 - SCI ; SCOPUS [o1] 2008 Malvindi, M. - Carbone, L. - Quarta, A. - Tino, A. - Manna, L. - Pellegrino, T. - Tortiglione, C.: Rod-shaped nanocrystals elicit neuronal activity in vivo. In: Small, Vol. 4, No. 10, 2008, s. 1747-1755 - SCI ; SCOPUS [o1] 2008 Pena, J. - Ordaz, B.: Non-selective cation channel blockers: Potential use in nervous system basic research and therapeutics. In: Mini-Reviews in Medicinal Chemistry, Vol. 8, No. 8, 2008, s. 812-819 - SCI ; SCOPUS [o1] 2008 Ray, S. - Mishra, P. - Verma, D. - Gupta, A. - Wadhwa, S.: Nimodipine is more effective than nifedipine in attenuating morphine tolerance on chronic co-administration in the rat tail-flick test. In: Indian Journal of ExperimentalBiology, Vol. 46, No. 4, 2008, s. 219-228 - SCI ; SCOPUS [o1] 2008 Scriabine, A. - Triggle, D.: Neuronal L-Type Voltage-Gated Calcium Channels. In: Structure, Function, and Modulation of Neuronal Voltagegated Ion Channels, 2008, s. 3-34 - SCOPUS [o1] 2008 Strube, C. - Strube, C.: AAbsence of regulation of the T-type calcium current by Ca(v)1.1, beta(1a) and gamma(1) dihydropyridine receptor subunits in skeletal muscle cells. In: Pflugers Archiv European Journal of Physiology, Vol.455, No. 5, 2008, s. 921-927 - SCI ; SCOPUS [o1] 2008 Tikhonov, D. - Tikhonov, D. - Zhorov, B.: Molecular modeling of benzothiazepine binding in the L-type calcium channel. In: Journal of Biological Chemistry, Vol. 283, No. 25, 2008, s. 17594-17604 - SCOPUS [o1] 2008 Zhou, W. - Liu, X. - Lü, X. - Li, J. - Luo, Q. - Zeng, S.: Monitor and control of neuronal activities with femtosecond pulse laser. In: Chinese Science Bulletin, Vol. 53, No. 5, 2008, s. 687-694 - SCOPUS [o1] 2009 Andrade, A. - Sandoval, A. - González-Ramírez, R. - Lipscombe, D. - Campbell, K. - Felix, R.: The alpha(2)delta subunit augments functional expression and modifies the pharmacology of Ca(V)1.3 L-type channels. In: Cell Calcium, Vol.46, No. 4, 2009, s. 282-292 - SCI ; SCOPUS [o1] 2009 Cairrao, E. - Santos-Silva, A. - Alvarez, E. - Correia, I. - Verde, I.: Isolation and culture of human umbilical artery smooth muscle cells expressing functional calcium channels. In: In Vitro Cellular and Developmental Biology -Animal, Vol. 45, No. 3-4, 2009, s. 175-184 - SCI ; SCOPUS 2 [o1] 2009 Cheng, R. - Tikhonov, D. - Zhorov, B.: Structural model for phenylalkylamine binding to L-type calcium channels. In: Journal of Biological Chemistry, Vol. 284, No. 41, 2009, s. 28332-28342 - SCI ; SCOPUS [o1] 2009 Huc, S. - Monteil, A. - Bidaud, I. - Barbara, G. - Chemin, J. - Lory, P.: Regulation of T-type calcium channels: Signalling pathways and functional implications. In: Biochimica Et Biophysica Acta - Molecular Cell Research, Vol. 1793,No. 6, 2009, s. 947-952 - SCI ; SCOPUS [o1] 2009 Lee, K. - Moreau, M. - Néant, I. - Bibonne, A. - Leclerc, C.: FGF-activated calcium channels control neural gene expression in Xenopus. In: Biochimica Et Biophysica Acta - Molecular Cell Research, Vol. 1793, No. 6, 2009, s. 1033-1040- SCOPUS [o1] 2009 Motagally, M. - Neshat, S. - Lomax, A.: Inhibition of sympathetic N-type voltage-gated Ca2+ current underlies the reduction in norepinephrine release during colitis. In: American Journal of Physiology - Gastrointestinal and LiverPhysiology, Vol. 296, No. 5, 2009, Art. No. G1077-G1084 - SCI ; SCOPUS [o1] 2009 Navarro-Gonzalez, M. - Grayson, T. - Meaney, K. - Cribbs, L. - Hill, C.: Non-l-type voltage-dependent calcium channels control vascular tone of the rat basilar artery. In: Clinical and Experimental Pharmacology and Physiology, Vol.36, No. 1, 2009, s. 55-66 - SCI ; SCOPUS [o1] 2009 Tikhonov, D. -
Load more

Recommended publications
  • C:Hofmann\1Lithof.Doc 27.02.2010
    1 C:Hofmann\1Lithof.doc 27.02.2010 List of Publications Dissertation Hofmann, F. (1968) "Die Wirkung einiger Colchizinderivate auf den Mäuse-Ascites-Tumor" Medizinische Fakultät der Universität Heidelberg Habilitation Hofmann, F. (1977) "Characterisierung der cAMP-abhängigen Protein-kinasen" Fakultät für Theoretische Medizin, Universität Heidelberg I Referierte Arbeiten Hofmann, F., Sold, G. (1972) "A protein kinase activity from rat cerebellum stimulated by guanosine-3`:5`- monophosphate" Biochem. Biophys.Res.Comm. 49, 1100-1107 Sold, G., Hofmann, F. (1974) "Evidence for a guanosine-3`:5`-monophosphate-binding protein from rat cerebellum" Eur.J.Biochem. 44, 143-149 Shizuta, Y., Beavo, J.A., Bechtel, P.J., Hofmann, F., Krebs, E.G. (1975) "Reversibility of the adenosine-3`:5`- monophosphate-dependent protein kinase reaction" J.Biol.Chem. 250, 6891-6896 Hofmann, F., Beavo, J.A., Bechtel, P.J., Krebs E.G. (1975) "Comparison of adenosine-3`:5`-monophosphate-dependent protein kinases from rabbit skeletal and bovine heart muscle" J.Biol.Chem. 250, 7795-7801 Hofmann, F., Bechtel, P.J., Krebs, E.G. (1977) "Concentrations of cyclic AMP-dependent protein kinase subunits in various tissues" J.Biol.Chem. 252, 1441-1447 Schwechheimer, K., Hofmann, F. (1977) "Properties of regulatory subunit of cyclic AMP-dependent protein kinase (peak I) from rabbit skeletal muscle prepared by urea treatment of the holoenzyme" J. Biol. Chem. 252, 7690-7696 Flockerzi, V., Speichermann, N., Hofmann, F. (1978) "A guanosine-3`:5`monophosphate-dependent protein kinase from bovine heart muscle" J.Biol.Chem. 253, 3395-3399 Schmidt-Gayk, H., Löhrke, H., Fischkal, A., Goerttler, K., Hofmann F. (1979) "Urinary cyclic AMP and bone histology in Walker Carcinosarcoma: Evidence of parathyroid hormone-like activity" Eur.J.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • A Homology Model of the Pore Domain of a Voltage-Gated Calcium Channel Is Consistent with Available SCAM Data
    A r t i c l e A homology model of the pore domain of a voltage-gated calcium channel is consistent with available SCAM data Iva Bruhova and Boris S. Zhorov Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario L8N 3Z5, Canada In the absence of x-ray structures of calcium channels, their homology models are used to rationaliz­e experimental data and design new experiments. The modeling relies on sequence alignments between calcium and potassium channels. Zhen et al. (2005. J. Gen. Physiol. doi:10.1085/jgp.200509292) used the substituted cysteine accessibility method (SCAM) to identify pore-lining residues in the Cav2.1 channel and concluded that their data are inconsis- tent with the symmetric architecture of the pore domain and published sequence alignments between calcium and potassium channels. Here, we have built Kv1.2-based models of the Cav2.1 channel with 2-(trimethylammonium)ethyl methanethiosulfonate (MTSET)-modified engineered cysteines and used Monte Carlo energy minimiz­ations to predict their energetically optimal orientations. We found that depending on the position of an engineered cyste- ine in S6 and S5 helices, the ammonium group in the long flexible MTSET-modified side chain can orient into the inner pore, an interface between domains (repeats), or an interface between S5 and S6 helices. Different local ­environments of equivalent positions in the four repeats can lead to different SCAM results. The reported current inhibition by MTSET generally decreases with the predicted distances between the ammonium nitrogen and the pore axis. A possible explanation for outliers of this correlation is suggested.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Calcium Channel Blockers for Bipolar Disorder: a Systematic Review And
    Calcium channel blockers for bipolar disorder: a systematic review and meta-analysis (Protocol) Andrea Cipriani,1 Mary-Jane Attenburrow,1 James Stefaniak,1 Kate Saunders,1 Sarah Stockton,1 Priyanka Panchal,1 Paul Harrison,1 John R Geddes1 1 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK (Version 2.1, March 2015) Background Bipolar disorder is a chronic, recurrent affective disorder in which there are mood swings between elevation and depression that are not caused by medication or physical comorbidities (Phillips and Kupfer 2013). The lifetime prevalence rate for bipolar disorder is approximately 1% in the general public; intriguingly, prevalence rates of bipolar disorder remain relatively constant between countries despite more widely varying rates of major depression (Merikangas 2011). Whilst the aetiopathogenesis of bipolar disorder has not been fully elucidated, there is clearly a strong genetic component (Craddock and Sklar 2013). Mood episodes normally start in the third decade of life and so bipolar disorder causes severe social distress; indeed, it accounted for more than 12 million Disability-Adjusted Life Years globally in 2010 alone (Murray 2012). Needless to say, such disability poses significant economic costs (Gonzalez-Pinto, Dardennes et al. 2010). Pharmacological treatment options are of great importance in bipolar disorder (Geddes and Miklowitz 2013). Treatment is invariably long term and often lifelong. Lithium remains a first line mood stabiliser in the preventative treatment of bipolar mood episodes (Geddes and Miklowitz 2013). However, approximately one third of patients do not respond adequately to lithium therapy. Various second generation antipsychotics and anticonvulsants were often trialled but with varying, not to say limited, efficacy (Geddes and Miklowitz 2013).
    [Show full text]
  • Permanently Charged Sodium and Calcium Channel Blockers As Anti-Inflammatory Agents
    (19) TZZ ¥Z¥_T (11) EP 2 995 303 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.03.2016 Bulletin 2016/11 A61K 31/165 (2006.01) A61K 31/277 (2006.01) A61K 45/06 (2006.01) A61P 25/00 (2006.01) (2006.01) (2006.01) (21) Application number: 15002768.8 A61P 11/00 A61P 13/00 A61P 17/00 (2006.01) A61P 1/00 (2006.01) (2006.01) (2006.01) (22) Date of filing: 09.07.2010 A61P 27/02 A61P 29/00 A61P 37/08 (2006.01) (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • WOOLF, Clifford, J. GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Newton, MA 02458 (US) PL PT RO SE SI SK SM TR • BEAN, Bruce, P. Waban, MA 02468 (US) (30) Priority: 10.07.2009 US 224512 P (74) Representative: Lahrtz, Fritz (62) Document number(s) of the earlier application(s) in Isenbruck Bösl Hörschler LLP accordance with Art. 76 EPC: Patentanwälte 10797919.7 / 2 451 944 Prinzregentenstrasse 68 81675 München (DE) (71) Applicants: • President and Fellows of Harvard College Remarks: Cambridge, MA 02138 (US) This application was filed on 25-09-2015 as a • THE GENERAL HOSPITAL CORPORATION divisional application to the application mentioned Boston, MA 02114 (US) under INID code 62. • CHILDREN’S MEDICAL CENTER CORPORATION Boston, Massachusetts 02115 (US) (54) PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS (57) The present invention relates to a composition or a kit comprising N-methyl etidocaine for use in a method for treating neurogenic inflammation in a patient, wherein the kit further comprises instructions for use.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]